Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Immunogenicity Testing Guidance Is High-Wire Act For Brand Industry

Executive Summary

The biotech industry faces a tightrope challenge in commenting on FDA's draft guidance on assay development for immunogenicity testing of therapeutic proteins. Companies want clarity from the agency, as well as limits to the scope of the guidelines. But firms also want to make sure that however the lines are drawn, follow-on biologics have strict testing requirements
Advertisement

Related Content

Follow-On Biologics One Possible Fruit Of FDA-Northeastern Collaboration
Follow-On Biologics One Possible Fruit Of FDA-Northeastern Collaboration
Follow-On Biologics One Possible Fruit Of FDA-Northeastern Collaboration
FDA Biosimilars Program Gets Seed Money In Administration's FY '11 Budget
Genzyme Receives Complete Response, Warning Letters For Lumizyme

Topics

Advertisement
UsernamePublicRestriction

Register

PS051930

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel